HRT Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-46,556
Closed -$13M – 4223
2026
Q1
$13M Buy
+46,556
New +$13.4M 0.03% 516
2025
Q4
– Sell
-25,739
Closed -$7.22M – 3203
2025
Q3
$7.22M Sell
25,739
-49,079
-66% -$13.4M 0.03% 513
2025
Q2
$18.1M Buy
74,818
+16,085
+27% +$3.8M 0.08% 167
2025
Q1
$14.3M Buy
+58,733
New +$17.7M 0.09% 168
2024
Q4
– Sell
-44,520
Closed -$14.9M – 2449
2024
Q3
$14.9M Buy
+44,520
New +$14.1M 0.07% 172
2024
Q2
– Sell
-2,053
Closed -$710K – 2237
2024
Q1
$710K Buy
2,053
+355
+21% +$117K ﹤0.01% 1066
2023
Q4
$548K Sell
1,698
-16,447
-91% -$5.16M ﹤0.01% 1308
2023
Q3
$6.5M Buy
18,145
+15,320
+542% +$5.91M 0.06% 215
2023
Q2
$1.07M Sell
2,825
-3,406
-55% -$1.39M 0.01% 915
2023
Q1
$2.98M Buy
6,231
+4,856
+353% +$2.27M 0.04% 430
2022
Q4
$578K Buy
1,375
+39
+3% +$15.7K 0.01% 1316
2022
Q3
$557K Buy
+1,336
New +$666K 0.01% 1365
2022
Q2
– Sell
-933
Closed -$525K – 2946
2022
Q1
$525K Sell
933
-4,572
-83% -$2.76M ﹤0.01% 1602
2021
Q4
$4.16M Buy
+5,505
New +$4.12M 0.02% 352
2021
Q3
– Sell
-4,951
Closed -$3.19M – 3284
2021
Q2
$3.19M Buy
+4,951
New +$3.01M 0.03% 430
2021
Q1
– Sell
-1,604
Closed -$935K – 2696
2020
Q4
$935K Buy
+1,604
New +$913K 0.02% 714
2020
Q3
– Sell
-22,444
Closed -$10.1M – 1900
2020
Q2
$10.1M Buy
+22,444
New +$9.9M 0.3% 63

Other funds holding BIO

HRT Financial's BIO Position: Q2 2026 in Review

HRT Financial sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 46,556 shares — an estimated $13M sold.

HRT Financial first reported a position in BIO in Q2 2020 and held it in 17 quarters. The position peaked at $18.1M in Q2 2025. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • HRT Financial reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 46,556 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $13M.
  • HRT Financial first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 17 quarters.
  • HRT Financial's Bio-Rad Laboratories Class A position peaked at $18.1M in Q2 2025.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.